Fenbendazole and Ivermectin for Pancreatic Cancer Success Stories: 51 Case Reports (October 2026 Update)
Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Pancreatic Cancer: A Compiled Case Series of 51 Patients. OneDayMD Integr Oncol Rev. 2026;1(1). Updated October 2026. Introduction Pancreatic cancer is among the most aggressive and difficult cancers to treat, particularly in its later stages. Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is a cancer which is difficult to effectively treat as it is often detected late in the disease process. Almost all PDACs (over 90%) have activating mutations in the GTPase gene KRAS . Pancreatic cancer has a high mortality rate and is often resistant to conventional treatments. Standard therapeutic options include surgical resection, chemotherapy, radiation therapy, and targeted therapy for pancreatic cancer with actionable mutations; yet survival rates remain low ...